Summary
12.72 -0.13(-1.01%)05/17/2024
OptimizeRx Corp (OPRX)
OptimizeRx Corp (OPRX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.74 | 5.72 | -2.75 | -28.21 | 11.74 | -25.69 | -3.53 | -9.96 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 10.81 | |
| Open | 10.69 | |
| High | 10.87 | |
| Low | 10.56 | |
| Volume | 56,505 | |
| Change | 0.19 | |
| Change % | 1.74 | |
| Avg Volume (20 Days) | 149,142 | |
| Volume/Avg Volume (20 Days) Ratio | 0.38 | |
| 52 Week Range | 6.92 - 16.65 | |
| Price vs 52 Week High | -35.11% | |
| Price vs 52 Week Low | 56.14% | |
| Range | 1.08 | |
| Gap Up/Down | -0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 232 | |
| EBIDTA | 4,340,601 | |
| PE Ratio | 827.3134 | |
| PEG Ratio | 1.4514 | |
| WallStreet Target Price | 103.00 | |
| Book Value | 7.1540 | |
| Earnings Per Share | 0.0670 | |
| EPS Estimate Current Quarter | 0.1300 | |
| EPS Estimate Next Quarter | 0.2500 | |
| EPS Estimate Current Year | 0.4300 | |
| EPS Estimate Next Year | 0.8500 | |
| Diluted EPS (TTM) | 0.0670 | |
| Revenues | ||
| Profit Marging | 0.0194 | |
| Operating Marging (TTM) | 0.0411 | |
| Return on asset (TTM) | 0.0155 | |
| Return on equity (TTM) | 0.0128 | |
| Revenue TTM | 57,406,104 | |
| Revenue per share TTM | 3.4680 | |
| Quarterly Revenue Growth (YOY) | 0.5330 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 24,105,421 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 827.3134 | |
| Forward PE | 72.4638 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 8.0330 | |
| Revenue Enterprise Value | 16.2706 | |
| EBITDA Enterprise Value | 292.9228 | |
| Shares | ||
| Shares Outstanding | 17,769,500 | |
| Shares Float | 15,509,080 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 12.72 | |
| Institutions (%) | 78.93 | |
05/14 23:21 EST - seekingalpha.com
OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2024 Earnings Conference Call May 14, 2024 2:30 PM ET Company Participants William Febbo - CEO Edward Stelmakh - CFO Steve Silvestro - President Andrew D'Silva - SVP of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Eric Martinuzzi - Lake Street David Grossman - Stifel Constantine Davides - Citizen JMP Stephanie Davis - Barclays William Wood - B. Riley Securities Operator Good afternoon, everyone, and thank you for joining OptimizeRx's First Quarter Fiscal 2024 Earnings discussion.
OptimizeRx Corporation (OPRX) Q1 2024 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2024 Earnings Conference Call May 14, 2024 2:30 PM ET Company Participants William Febbo - CEO Edward Stelmakh - CFO Steve Silvestro - President Andrew D'Silva - SVP of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Eric Martinuzzi - Lake Street David Grossman - Stifel Constantine Davides - Citizen JMP Stephanie Davis - Barclays William Wood - B. Riley Securities Operator Good afternoon, everyone, and thank you for joining OptimizeRx's First Quarter Fiscal 2024 Earnings discussion.
05/14 16:01 EST - globenewswire.com
OptimizeRx Reports First Quarter 2024 Financial Results
WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period.
OptimizeRx Reports First Quarter 2024 Financial Results
WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period.
05/13 11:01 EST - zacks.com
Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?
The consensus price target hints at a 34.8% upside potential for OptimizeRx (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?
The consensus price target hints at a 34.8% upside potential for OptimizeRx (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
05/06 16:30 EST - globenewswire.com
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
04/26 07:30 EST - globenewswire.com
OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, is providing a business update for 2024 and is preannouncing preliminary, unaudited results for select financials for the first quarter of 2024.
OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, is providing a business update for 2024 and is preannouncing preliminary, unaudited results for select financials for the first quarter of 2024.
04/23 10:36 EST - zacks.com
After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
04/22 10:36 EST - zacks.com
Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
04/18 07:30 EST - globenewswire.com
OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2024.
OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2024.
04/16 07:00 EST - globenewswire.com
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the fourth quarter and full year ended December 31, 2023.
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the fourth quarter and full year ended December 31, 2023.
04/11 07:30 EST - globenewswire.com
OptimizeRx Named America's Fastest-Growing Company for Fifth Year in a Row
WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has secured a coveted spot on the 2024 Financial Times' Americas' Fastest-Growing Companies list for a remarkable fifth consecutive year, ranking at 253.
OptimizeRx Named America's Fastest-Growing Company for Fifth Year in a Row
WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has secured a coveted spot on the 2024 Financial Times' Americas' Fastest-Growing Companies list for a remarkable fifth consecutive year, ranking at 253.
04/06 06:00 EST - investorplace.com
7 Top Undervalued Stocks Primed for a Multibagger Recovery
If you're looking for undervalued stocks, you don't have to look far, despite the rally. The past year or so has been a wild rollercoaster ride for investors.
7 Top Undervalued Stocks Primed for a Multibagger Recovery
If you're looking for undervalued stocks, you don't have to look far, despite the rally. The past year or so has been a wild rollercoaster ride for investors.
03/28 11:20 EST - seekingalpha.com
OptimizeRx Corporation (OPRX) Q4 2023 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q4 2023 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q4 2023 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q4 2023 Earnings Call Transcript
03/25 07:45 EST - headlinesoftoday.com
OptimizeRx Sets Fourth Quarter 2023 Conference Call
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, March 28, 2024, at 8:30 a.m. Eastern Time to discuss the preliminary, unaudited results for the fourth … The post OptimizeRx Sets Fourth Quarter 2023 Conference Call appeared first on Headlines of Today...
OptimizeRx Sets Fourth Quarter 2023 Conference Call
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, March 28, 2024, at 8:30 a.m. Eastern Time to discuss the preliminary, unaudited results for the fourth … The post OptimizeRx Sets Fourth Quarter 2023 Conference Call appeared first on Headlines of Today...
03/25 07:30 EST - globenewswire.com
OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, March 28, 2024, at 8:30 a.m. Eastern Time to discuss the preliminary, unaudited results for the fourth quarter.
OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, March 28, 2024, at 8:30 a.m. Eastern Time to discuss the preliminary, unaudited results for the fourth quarter.
03/12 02:35 EST - headlinesoftoday.com
OptimizeRx Provides an Update on the Timing of Earnings
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today provided an update on the anticipated timeline for its financial reporting and reaffirms prior revenue and adjusted EBITDA estimates for FY2023. The Company …
OptimizeRx Provides an Update on the Timing of Earnings
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today provided an update on the anticipated timeline for its financial reporting and reaffirms prior revenue and adjusted EBITDA estimates for FY2023. The Company …
03/11 16:30 EST - globenewswire.com
OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today provided an update on the anticipated timeline for its financial reporting and reaffirms prior revenue and adjusted EBITDA estimates for FY2023.
OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today provided an update on the anticipated timeline for its financial reporting and reaffirms prior revenue and adjusted EBITDA estimates for FY2023.
03/04 15:51 EST - globenewswire.com
OptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community' Outreach Effort
WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced its collaboration with Walmart to support its Specialty Pharmacies of the Community (SPOCs) provider outreach initiative.
OptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community' Outreach Effort
WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced its collaboration with Walmart to support its Specialty Pharmacies of the Community (SPOCs) provider outreach initiative.
01/25 07:30 EST - globenewswire.com
OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape
WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company's growth plans.
OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape
WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company's growth plans.
01/11 08:16 EST - zacks.com
New Strong Buy Stocks for January 11th
ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.
New Strong Buy Stocks for January 11th
ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.